近日,据港媒消息,由强生旗下创投公司财政支持的医疗器材公司 HistoSonics 考虑最快今年在美国进行首次公开募股(IPO)。消息人士透露,HistoSonics 已与投资银行展开讨论,评估潜在股票出售,计划筹集数亿美元,上市时寻求数十亿美元估值。据悉,HistoSonics 是一家由强生支持的医疗设备公司,其核心技术组织碎化术(Histotripsy)是一种利用高强度超声波精确破坏癌细胞,却...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.